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The  TGR5  receptor  (or  GP-BAR1,  or M-BAR)  was  characterized  ten  years  ago  as  the ﬁrst  identiﬁed  G-
coupled  protein  receptor  speciﬁc  for bile  acids.  TGR5  gene  expression  is  widely  distributed,  including
endocrine  glands,  adipocytes,  muscles,  immune  organs,  spinal  cord,  and  the  enteric  nervous  system.  The
effect of  TGR5  activation  depends  on  the tissue  where  it is  expressed  and  the signalling  cascade  that  iteywords:
ile acids
iabetes
nﬂammation
otility
induces.  Animal  studies  suggest  that  TGR5  activation  inﬂuences  energy  production  and thereby  may  be
involved  in obesity  and diabetes.  TGR5  activation  also  inﬂuences  intestinal  motility.  This  review  provides
an  overview  of TGR5-bile  acid  interactions  in health  as  well  as  the  possible  involvement  of TGR5  in  human
disease.
© 2013 Editrice  Gastroenterologica  Italiana  S.r.l. Published  by  Elsevier  Ltd.  All  rights  reserved.
GR5 receptor
. Introduction
The TGR5 receptor is the ﬁrst known G-protein coupled recep-
or speciﬁc for bile acids. Since its identiﬁcation in 2002, TGR5
as been found to be ubiquitously expressed in humans and ani-
als, and to activate various intracellular signalling pathways upon
nteraction with bile acids. In animals, initial experimental studies
evealed that TRG5 activation plays a role in the regulation of basal
etabolism and energy expenditure; TGR5 is now recognized as a
otential target for the treatment of metabolic disorders, such as
ype 2 diabetes. In addition, the ability of TGR5 to lower the levels of
roinﬂammatory cytokines in monocytes has opened new insights
nto the modulatory role of bile acids in pathology where inﬂam-
atory processes play a central role, including colitis and atheroma
evelopment. TGR5 activation has also been shown to inﬂuence
xperimental cholesterol gallstone formation in mice and found to
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ttp://dx.doi.org/10.1016/j.dld.2013.10.021stimulate bicarbonate secretion by cholangiocytes. Several recent
reviews have addressed conditions in which TGR5 has emerged as
a new target for pharmaceutical agents ([1:p. 5,2–4]). The intent of
the present review is to provide a summary of the currently avail-
able knowledge on TGR5 biology and to relate this information to
the possible involvement of TGR5 in human diseases.
2. TGR5 discovery
In 1999, the ﬁeld of bile acids experienced a change in thinking
when bile acid function moved beyond that of digestive surfac-
tants. Bile acids were found to be signalling molecules, acting as
hormones and regulatory ligands. This paradigm shift was spurred
by the discovery of the dominant nuclear receptor for bile acids, the
farnesoid X receptor (FXR) [5]. Since then, convergent studies have
established that FXR is involved in the regulation of genes acting in
multiple metabolic pathways [6,7]. Three years after the discovery
of FXR, Maruyama et al. described a cell membrane G-protein cou-
pled receptor (GPCR) that was  activated by bile acids. This receptor
is generally named the membrane-bile acid receptor (M-BAR) [8],
or TGR5 [9], rather than the Gprotein bile acid-activated receptor
(GP-BAR1) [10,11]. It is important to note that GP-BAR1 remains the
ofﬁcial designation for Homo sapiens in the NIH gene database and
in the recommendations of the HUGO Gene Nomenclature Com-
mittee [12].
 Ltd. All rights reserved.
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The existence of a cell surface receptor activated by bile
cids was previously suspected, given the differential immuno-
uppressive effects of bile acids in immune cells assessed in vitro.
henodeoxycholic and deoxycholic acids were found to decrease
he production of interleukin 6 (IL-6) and tumour necrosis factor
lpha (TNF-)  from macrophages, whereas ursodeoxycholic acid,
 more hydrophilic bile acid, had a much smaller effect [13,14].
ased on the sequence of a probable GPCR identiﬁed in the Human
enome database (GenBank), Maruyama et al. [8] cloned the TGR5
eceptor in human embryonic kidney HEK 293 cells, and charac-
erized the variations in binding afﬁnity of individual bile acids
o TGR5. These ﬁndings were conﬁrmed by studies in Chinese
amster Ovarian cells (CHO) co-transfected with a reporter gene
cyclic Adenosine Monophospate (cAMP) responsive element fused
o the luciferase gene), and with an expression vector of the human
ypothetical GPCR sequence [9]. Among thousands of compounds
creened, bile acids were the only ones that triggered a speciﬁc
ncrease in luciferase activity due to cAMP production. Similarly, a
o-transfection assay of CHO cells with the rat TGR5 cDNA sequence
emonstrated that rat TGR5 emerged as the speciﬁc bile acid recep-
or [9]. Additional experiments using a fusion protein of TGR5 and
reen ﬂuorescent protein (GFP) identiﬁed the localization of TGR5
n the plasma membrane and its internalization upon treatment
ith taurolithocholic acid. However, this internalization process
emains controversial because, to date, it has not been reproduced
y other teams, and subsequent data have shown that TGR5 can be
epeatedly activated.
. TGR5 gene and structure
Maruyama et al. as well as Kawamata et al. identiﬁed the puta-
ive coding sequence using the GenBank DNA database approach
o screen amino acid sequences of known GPCRs [8,9]. The coding
equence of the TGR5 gene contains 993 base pairs, encoding a pro-
ein of 330 amino acids with the predicted seven transmembrane
omains, a feature that is characteristic of GPCRs. In humans, the
GR5 gene is located on chromosome 2q35, and the cDNA sequence
hared almost complete homology (>80%) with that of bovid, rab-
it, and rodent species, showing a high structural conservation
mong mammals (Fig. 1) [9]. The crystal structure of TGR5 is not
et available to allow modelling of the binding domain. However,
 homology model of the 3D structure of the binding domain has
een recently proposed using the TGR5 amino acid sequence (Fig. 2)
15].
. Distribution and regulation of TGR5 gene expression
Mapping studies indicate that TGR5 gene expression is ubiqui-
ous, both in animals and humans. The initial expression proﬁle
ndicated a wide tissue distribution of TGR5 gene expression,
ncluding endocrine glands, adipocytes, muscles, as well as immune
rgans like spleen and lymph nodes (Fig. 3 A) [9]. In C57/BL6 mice,
GR5 mRNA is detected in visceral organs (Fig. 3B) including the
ut and the gallbladder (Fig. 3C) [10,16]. TGR5 gene expression
s also found in the brain and spinal cord in rodents and humans
10,16–18] and is densely expressed in the enteric nervous system
f mice [19].
At the protein level, an immunohistochemical study in mice
howed that TGR5 immunoreactivity is widely distributed through-
ut the gastrointestinal tract, with a prominent expression in
he enteric nervous system [19]. In particular, the submucosal
erve plexus of the small and large intestine display TGR5
mmunoreactivity in more than 80% of neurons. In the myenteric
lexus, TGR5 immunoreactivity is mainly located in the inhibitory
eurons and descending neurons. The enteric localization of TGR5 Disease 46 (2014) 302–312 303
provides a neuroanatomical support to earlier recognition of the
secretory and motor effect of bile acids as a component of the intra-
mural nervous reﬂex [20,21]. In the rat liver, the TGR5 receptor
has been identiﬁed on the plasma membrane of liver sinusoidal
endothelial cells [22], as well as on the apical membrane and pri-
mary cilium of cholangiocytes [23], as well as on biliary epithelial
cells [24] and Kupffer cells [25]. In mice spinal cord, the distribution
in sacral and lumbar segments has received particular attention,
and TGR5 immunoreactivity was found to be located in neuronal
cell bodies of the laminae I, II, and V of the dorsal horn, and lamina
X [18].
At present, little is known about the regulation of TGR5
expression in the whole organism in response to physiologi-
cal or pathological conditions, as regulation of expression has
been assessed mainly in cultured cells. Ammonium ions down-
regulate mRNA expression in cultured astrocytes in a dose and
time-dependent manner after 48 h [17]. The steroid 5-beta-
pregnan-3-alpha-ol-20-one, which is also a potent TGR5 ligand, can
decrease TGR5 gene expression after incubation for 72 h [17].
5. TGR5 agonists
Among the family of steroids, the most powerful endogenous
agonists identiﬁed for the TGR5 receptor are taurine and glycine-
conjugated and unconjugated bile acids. Activation of TGR5 by
bile acids was characterized by measuring cAMP production in
CHO [9] and HEK293 [4] cell lines transfected with human TGR5
cDNA in an expression vector. TGR5 showed a dose-dependent
activation by bile acids, with the following rank order of potency:
lithocholic acid ≥ deoxycholic acid > chenodeoxycholic acid > cholic
acid. Of note, deoxycholic acid is a secondary bile acid formed by
bacterial dehydroxylation of cholic acid; lithocholic acid is formed
by the analogous dehydroxylation of chenodeoxycholic acid; cholic
and chenodeoxycholic acids are the dominant primary bile acids
in humans. Activation was  greater for taurine-conjugated than
unconjugated bile acids, and these in turn were more potent than
glycine-conjugated bile acids. It should be noted that taurine-
conjugation of bile acids is the default mode of conjugation in
non-mammalian orders. Conversely, glycine conjugation is uncom-
mon, occurring mainly in bovids and primates (Fig. 4) [9]. Oleanolic
acid is a triterpene molecule extracted from olive leaves with a
shape resembling that of lithocholic acid; it has also been identi-
ﬁed as a TGR5 agonist in a luciferase assay based on studies using
CHO cell lines transfected with TGR5 expression plasmid [26].
In addition to bile acids and oleanolic acid, more potent selec-
tive TGR5 agonists derived from natural C24 bile acids have also
been recently described by researchers at the University of Peru-
gia, Italy [27,28]. So far, the most speciﬁc agonist synthesized
from cholic acid is the 6-ethyl-23(S)-methylcholic acid (S-EMCA).
Another modiﬁed bile acid derivative, INT 767, has been synthe-
sized and activates both TGR5 and FXR [29]. Further evaluation
of the dual agonist showed the absence of cytotoxicity in HepG2
cells, its resistance to enzymatic cleavage, and the absence of
inhibition of the human ether-á-go-go-related gene (hERG) potas-
sium channel [29]. Additionally, other synthetic agonists have
been developed as potential new targets for type 2 diabetes,
namely 3-aryl-4-isoxazolecarboxamides. These are non-bile-acid-
related compounds that display potent agonist afﬁnity with human
TGR5 as shown in a cAMP assay in U2-OS transfected cells. The
compounds have satisfactory aqueous solubility, a low molecular
weight, and a high membrane permeability [30,31]. The class of the
2-aryl-3-aminomethylquinolines has also been tested in the same
in vitro assay type [32]. However, none of these agonists have as
yet been tested in clinical trials. The antibiotic ciproﬂoxacin has
been proposed as a TGR5 ligand, although its binding afﬁnity and
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ignalling through cAMP assay in cell lines is yet to be demonstrated
33].
. Intracellular signalling cascades induced by TRG5
ctivation in eukaryotic cells
Bile acid binding to TGR5 results in the activation of the adenylyl
yclase cAMP signalling pathways [9]. In addition, other cell-
peciﬁc activation signalling cascades are also activated [22,24,25].
n the pancreatic -cell line MIN6, TGR5 ligands, oleanolic acid,
nd S-EMCA selectively activated G(s) and increased intracellular
AMP, calcium, and phosphoinositide hydrolysis that was  blocked
y NF449 (a selective G(s) inhibitor) or U 73122 (PI hydrolysis
nhibitor) [34]. In cultured neurons, a cAMP increase is accom-
anied by a rise in intracellular calcium, which may  induce the
roduction of reactive nitrogen oxide species [17]. In liver sinu-
oidal endothelial cells, bile acids activate the phosphorylation of
ndothelial nitric oxide synthase (NOS) through TGR5 activation
nd cAMP release, leading to nitric oxide (NO) synthesis [22]. In
allbladder smooth muscle, conversely to neurons and -cells lines,
GR5 activation lowers the intracellular calcium levels, decreasingman, bovine, rabbit, rat, and mouse TGR5.
ecular Biology, Journal of Biological Chemistry, Kawamata et al., J Biol Chem. 2003
the rhythmic discharge of intracellular Ca2+ necessary to induce
contraction [35].
7. Phenotype of the TGR5 knockout mice
In the absence of a selective receptor antagonist, the targeted
disruption of the TGR5 receptor was performed in C57BL/6 mice
[10,16]. TGR5−/− mice display a healthy and fertile phenotype with
normal development. Light microscopic examination of organs’
tissue sections did not reveal developmental abnormalities in
TGR5−/− compared to TGR5+/+ mice, suggesting that TGR5 is not
required for normal organogenesis. Other cellular parameters such
as haematological indices and routine serum chemistries blood
(bilirubin, low and high density lipoproteins, triglycerides, and bile
acids) were similar in knockout and wild type (WT) mice, as were
measurements of glucose and other metabolites in the urines [10].
However, the liver mRNA expression of various cytochromes and
proteins involved in the hepatic synthesis and transport of bile acids
was higher in TGR5−/− than in WT  mice, especially Cyp7a1, the rate-
limiting enzyme in bile acid synthesis. This should logically lead to
an increase of bile acid synthesis. However, the bile acid pool was
H. Duboc et al. / Digestive and Liver
Fig. 2. 3D structure of TGR5. The receptor comprises seven transmembrane helices
(TMH1-7), three extracellular loops (ECL1–3), contributing to ligand binding, and
three intracellular loops (ICL1–3) involved in mediating the signal to downstream
signalling molecules. ICL3 and the N- and C-terminal segments are structurally
ﬂexible and disordered (broken lines).
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srom PLOS one, Hov et al., Mutational characterization of the bile acid receptor
GR5 in primary sclerosing cholangitis. PLoS ONE. 2010;5(8):e12403 [15], with
ermission.
ot increased, suggesting that other homeostatic mechanisms may
e involved in the knockout animals [10,16].
Phenotypic sex-speciﬁc differences were observed in param-
ters such as weight and metabolism, as both the heterozygous
GR5−/+ and homozygous TGR5−/− female mice exhibited a sig-
iﬁcantly higher body weight change than males in response to
 high fat diet [16]. This was due to excessive fat accumulation
espite an equivalent food intake and locomotor activity, suggest-
ng a decrease in energy expenditure, without any explanation for
his sex-related difference [16]. There is evidence that in TGR5
nockout mice fed with a high-fat diet, males exhibit impaired
nsulin sensitivity while females show improved insulin sensitiv-
ty. These data suggest a sex-related difference in the regulation of
etabolic disorders through TGR5 [36].
In the gut, where TGR5 is densely expressed, microscopic alter-
tions in the appearance of colonic mucosa occurred in TGR5−/−
ice, including the abnormal morphology of colonic mucous cells
ssociated with the altered molecular architecture of epithelial
ight junctions. This led to a signiﬁcant increase in intestinal perme-
bility at the age of 12 months, associated with an overexpression of
he main proteins of the tight junctions (zonulin-1 and occluding)
n colonic epithelial cells; these characteristics showed a discon-
inuous pattern of distribution compared to WT  animals [33].
. Biological effects of TGR5 activation.1. Anti-inﬂammatory effects
The initial tissue screening that targeted TGR5 mRNA expres-
ion was performed in human monocytes [9]. Convergent ﬁndings Disease 46 (2014) 302–312 305
showed that TGR5 was  the receptor involved in the previously
known immunosuppressive effect of bile acids in immune cells [14].
Indeed, TGR5 activation lowered the pro-inﬂammatory cytokines
interleukin-1 (IL-1), IL-1, IL-6 and tumour necrosis factor-
(TNF-). These cytokines are known to be synthesized by Kupf-
fer cells in response to a lipopolysaccharide (LPS) challenge [25].
Of signiﬁcance, the synthesis of pro-inﬂammatory cytokines after
LPS stimulation is higher in isolated macrophages from TGR5−/−
than those from TGR5+/+ mice, further supporting the role of TGR5
signalling in the downregulation of the inﬂammatory response to
Gram-negative bacteria [37].
The anti-inﬂammatory effect of TGR5 is mediated by the inhi-
bition of the pro-inﬂammatory transcriptional nuclear factor-B
(NF-B) [37,38]. In macrophages from TGR5 knockout mice, the
mRNA levels of various pro-inﬂammatory genes targeted by NF-B
(inducible NOS, interferon-inducible protein, and IL-1) are higher
than to those in macrophages from WT  mice [38]. Likewise, in
the macrophage cell line RAW264.7, TGR5 activation inhibited NF-
B activation via the cAMP signalling pathway [37]. When TGR5
was activated or overexpressed, NF-B transcriptional activity was
inhibited after LPS treatment, and was  reversed in the presence
of cAMP inhibitors [37]. Bile acids’ interaction with TGR5 was also
shown to inﬂuence the differentiation of subtypes of dendritic cells
into cells with an anti-inﬂammatory phenotype [39]. Dendritic cells
are central regulators of the acquired and innate immunity, as
antigen presenting cells. During differentiation of monocytes iso-
lated from peripheral human blood into dendritic cells, the addition
of bile acids lead to reduced IL-12 production when stimulated
by bacterial antigen, in a dose-dependent manner. These effects
on differentiation were only induced if bile acids or a speciﬁc
TGR5-agonist was present at the start of culture, and were not
observed in terminally differentiated cells. In addition, the down-
regulation of TGR5 expression after differentiation into dendritic
cells supports a critical role of the TGR5 expressed on monocytes
in the initial phase of differentiation to dendritic cells [39].
8.2. Liver and biliary tree
TGR5 is also found in Kupffer cells and liver sinusoidal endothe-
lial cells, where it activates endothelial NOS and induces NO release
[22,25]. To date, TGR5 protein has not been detected in hepatocytes
[40] but was found in the biliary tree and gallbladder epithelia [24],
as well as in the apical membranes and primary cilium of cholan-
giocytes [23]. The proximity between synthesis and secretion of
ligands (bile acids) by the hepatocytes, and the site of action in
the biliary tree, where TGR5 is abundant, represent a paracrine
mode of action for bile acids within this organ [41]. At a cellu-
lar level, immunohistochemical detection on human gallbladder
showed that TGR5 is located in close proximity to the cystic ﬁbro-
sis transmembrane conductance regulator (CFTR) and the apical
sodium dependant bile salt uptake transporter (ASBT) [42]. Data
obtained by using the CFTR inhibitor and TGR5 agonist suggested
that TGR5 promotes biliary chloride secretion through CFTR [42].
As the primary cilium is a sensor regulating bile ﬂow and compo-
sition, TGR5 should be a key player in this sensing mechanism. A
recent study indicates that the genetic deletion of TGR5 abrogates
the usual increase of bile ﬂow, chloride, and bicarbonates secretion
observed after partial hepatectomy in mice, and leads to a slower
regeneration of the liver [43]. TGR5 is reported to be localized in
different subcellular compartments of the cholangiocytes (primary
cilia, plasma membrane, and subapical compartment), probably
associated with different effects varying with its complex cellu-
lar repartition. Experimentally, after TGR5 stimulation, the ciliary
localization is associated with lower cAMP levels and limits cili-
ated cholangiocytes’ proliferation; this is in contrast with the exact
opposite effects in nonciliated cholangiocytes [44]. A functional
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Fig. 3. (A–C) Comparison of TGR5 mRNA expression in human (A) and C57/BL6 mice (B and C) tissues.
From Copyright: The American Society for Biochemistry and Molecular Biology, Journal of Biological Chemistry, Kawamata et al., J Biol Chem. 2003 Mar  14;278(11):9435–40
[9] (A), “Reproduced with permission”: Maruyama T et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J Endocrinol. 2006
Oct;191(1):197–205. Copyright BioScientiﬁca Ltd. [16] (B), Reproduced with permission, 
Tetzloff  G, Levitan D, Murgolo N.J, Keane K, Davis Jr H.R, Hedrick J and Gustafson E.L (200
Biochemical Journal, 398 423–430 © the Biochemical Society [10] (C), with permission.
Fig. 4. Comparative dose response assay of induced by various bile acids in CHO-
TGR5 transfected cells. The ﬁgure summarizes the production of cAMP in CHO-TGR5
transfected cells by bile acids. LCA: lithocholic acid; DCA: deoxycholic acid; CDCA:
chenodeoxycholic acid; CA: cholic acid. T = taurine conjugated; G = glycine conju-
gated; F = free (unconjugated) bile acid.
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ype receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002 Nov
5;298(5):714–9 [8]. Copyright Elsevier.
tudy in mice showed that TGR5 decreased motility and increased
lling of the gallbladder [45]. Likewise, in ex vivo experiments TGR5
ctivation reduced the gallbladder’s smooth muscle contractility,
roviding evidence of an important role of TGR5 in stimulating
allbladder smooth muscle relaxation and ﬁlling [35].from Vassileva G, Golovko A, Markowitz L, Abbondanzo S.J, Zeng M,  Yang S, Hoos L,
6) Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation.
8.3. Energy homeostasis and metabolism
Watanabe et al.’s seminal observation established that TGR5
enhances energy expenditure, increases oxygen consumption, pre-
vents obesity, and decreases insulin resistance in a mice model of
obesity [46]. In human brown adipocytes and skeletal myocytes,
bile acids interact with TGR5 and thereby activate the key enzyme
iodothyronine deiodinase, that converts inactive thyroxine (T4)
into intracellular active tri-iodothyronine (T3), a major compo-
nent involved in cellular basal metabolism [46]. The protection
against insulin resistance has been ﬁrst attributed to intestinal
secretion of glucagon-like peptide 1 (GLP-1) induced through the
activation of TGR5. This was  demonstrated in an enteroendocrine
cell line, where TGR5 agonists increased GLP-1 release [47]. More-
over, evidence indicates that TGR5 is expressed in both mouse and
human pancreatic cells islets. In pancreatic -cells, TGR5 agonists
can induce insulin secretion through a cAMP/Ca2+ pathway [34],
conﬁrming the critical role of bile acids in glucose homeostasis.
Likewise, the TGR5 receptor agonist oleanolic acid, enhanced glu-
cose tolerance by lowering glucose and insulin levels in a mouse
model of obesity and diabetes [26]. These convergent ﬁndings point
to bile acid–TGR5 interaction as a key regulator endpoint of basal
metabolism regulation [48,49].8.4. Cell proliferation, apoptosis, and growth factors
Bile acids have been identiﬁed to interact with the epithelial
growth factor receptor (EGFR), as demonstrated in the colonic
H. Duboc et al. / Digestive and Liver
Fig. 5. Defecation frequency and whole gut transit time in WT and TGR5−/− mice.
Reproduced with permission, from Alemi F et al., The receptor TGR5 mediates the
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taurolithocolate (TLCA) increases the production of NO, consideredrokinetic actions of intestinal bile acids and is required for normal defecation in
ice. Gastroenterology. 2013 Jan;144(1):145–54 [59]. Copyright Elsevier.
pithelial cell line CaCo-2 cells and in cholangiocytes [50,51]. How-
ver, whether this represents an interaction with the TGR5 pathway
s still to be established.
Bile acids exert a protective effect against apoptosis in cholan-
iocytes [52,53]. In isolated sinusoidal endothelial cells, TGR5
ctivation increases the phosphorylation of the CD95 death recep-
or, which prevents CD95-dependent apoptosis [22,54]. In isolated
epatic stellate cells from rats, bile acids can trigger both prolif-
ration and apoptosis through EGFR [55]. However, these ﬁndings
ere obtained with sulphated lithocholic acid at a concentration
ar above that occurring in the space of Disse.
TGR5 is also an activator of mitogen protein kinases. In gastric
arcinoma cells treated with TGR5 small interference RNA, there
s a decrease in deoxycholic acid-induced EGFR phosphorylation,
hich is involved in mitogen protein kinases activation [56]. In
he chemical mouse model of liver carcinogenesis, using diethyl-
itrosamine to induce hepatocellular carcinoma, TGR5 activation
xerts a protective effect against tumour development through
he inhibition of the transcription factor STAT3 [57]. Importantly,
GR5 knockout mice had a higher incidence of diethylnitroamine
nduced hepatocellular carcinoma than WT  mice, and in these mice
TAT3 phosphorylation was 2-fold higher than in WT mice. At the
ellular level, when the human liver cancer cell line HepG2 was
ransfected with the TGR5 expression plasmid, the ligand-activated
GR5 inhibited cell growth and decreased STAT3 phosphoryla-
ion [57]. These ﬁndings may  be relevant to human diseases, as
hronic activation of phosphorylated STAT3 is frequently detected
n human liver tumours [58].
.5. Intestinal motility and secretion
Recent studies by Bunnett and Corvera indicate the involvement
f TGR5 in bile acids-induced motility [59]. Ex vivo, full-thickness
egments of mouse colon stimulated by various TGR5 agonists
nduced peristalsis in WT  mice, while this effect was  absent in
nockout mice. In vivo, TGR5−/− mice displayed a delayed colonic
ransit and a lower defecation frequency compared to WT (Fig. 5).
f mechanistic relevance was the demonstration that bile acids
ncreased the release of the peristaltic transmitters, namely 5-
ydroxytryptamine and calcitonin-gene related peptide, which
ere found in a ﬂat sheet preparation of mice distal colon. Of sig-
iﬁcance, the mechanically induced peristalsis was  not affected by
GR5 deletion, indicating a speciﬁc effect of bile acids on colon tran-
it. These ﬁndings point to TGR5 as playing a physiological role in
he regulation of propulsive motor function [59]. Presumably, this Disease 46 (2014) 302–312 307
effect is mediated by plasma bile acids, which increase threefold
postprandially.
In the same study, an observation showing that the faecal water
content is lower in TGR5 knockout mice suggests that TGR5 may
be critical in the regulation of the colonic water and electrolytes
efﬂux. A recent work studying the bile acid-induced chloride secre-
tion in the colon, by using a model of human colorectal cultured
cells (T84 cells), showed that the chloride efﬂux [60] from the api-
cal side uses CFTR as the ion transporter, through an intracellular
cAMP signalling pathway: by detecting the cellular TGR5 mRNA
expression, the authors suggested that this effect could be medi-
ated through TGR5. However, in the absence of a functional assay
using a speciﬁc TGR5 inhibitor, it was not possible to demonstrate
its effective implication in chloride secretion.
9. TGR5: relevance in diseases
The pleiotropic expression and biological actions induced by the
activation of TGR5 that was  demonstrated in animal models or dif-
ferentiated cell lines raise the question of whether TGR5 activation
may  alleviate or exacerbate speciﬁc human pathology as outlined
in Table 1 [1–4].
9.1. Metabolic and cardiovascular disorders
Since the report of its key role in the regulation of the thyroid
hormone cellular action and basal metabolism [46], the conditions
of obesity, insulin resistance, and type 2 diabetes appear to be
critically linked to TGR5 [49]. This is supported by the demon-
stration that TGR5 activation prevents obesity in mice [46], and
treatment with a TGR5 agonist improves glucose tolerance in mice
fed with a high-fat diet, as shown by the lowering of plasma glu-
cose levels [26]. The key observations that directly point at TGR5
as a target for the treatment of metabolic disorders are the exper-
imental evidences in animals that implicate TGR5 stimulation in
the secretion of both GLP-1 in the gut and insulin in the pancreas
[34,61]. In a diet-induced obesity mice model, TGR5 stimulation in
the distal colon (using enema with TGR5 agonists) induces a GLP-1
release associated with an increase of GLP-1 in portal blood [62].
These experimental data in animals were conﬁrmed by a clinical
study performed in healthy male volunteers, showing that a rec-
tal enema with sodium taurocholate rapidly increases circulating
GLP-1 concentrations, suggesting that bile acids activate colonic
enteroendocrine cells via TGR5 [63].
TGR5 appears relevant also for the pathogenesis of atheroscle-
rosis, but via a mechanism independent from the well-known
increased risk of atheroma development occurring in diabetes
[49]. The atheroma plaque composition depends on intimate
interactions between monocytes and arterial endothelium, where
pro-inﬂammatory mechanisms ﬁrst induce differentiation of
monocytes in macrophages, and then facilitate the accumu-
lation of lipids in their cytoplasm. TGR5 exerts a protective
effect against atheroma development in the mouse model of
atherosclerosis (LDL−/− mice) by curtailing inﬂammation and lipid
accumulation [37]. In such mice, TGR5 activation reduces the
size of atheroma plaques. A speciﬁc semi-synthetic TGR5 ago-
nist attenuates atherosclerosis in LDL−/− TGR5+/+ mice, but not
in double knockout mice (LDL−/− TGR5−/−). This is achieved by
decreasing the intraplaque inﬂammation, the macrophage count
within the plaque, and the macrophage activity [37]. Experimen-
tally, in bovine and human endothelial cells, the TGR5 agonistas a key antiatherogenic molecule [64].
Combined with the same protective effect against atheroma
plaque development induced by FXR, TGR5 activation appears to be
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Table 1
Summary of TGR5 localization, known signalling pathways, biological actions, and potential implications for human disease.
Reference Tissue or cell line
expressing TGR5
TGR5 intracellular actions TGR5 biological action Potential implications to
human disorder
[46] Brown adipocytes/skeletal
myocytes
Iodothyrionine deiodinase
activation
Conversion of inactive T4
in active T3
Enhance basal metabolism
[37,64,67] Arterial Suppress Inﬂammation Reduce development of
atheroma plaques
Decreased atherosclerosis
[26,47,61–63] Enteroendocrine cell Mitochondrial oxidative
phosphorylation
GLP-1 release Multiple GLP-1 actions:
improved diabetes control
[9,13,14,25,37–39] Monocytes/macrophages Decrease expression of
NFkB induced genes
Reduction of IL-1 , IL-1,
IL-6 and TNF-
Inﬂammatory diseases
improvement
[17] Brain neurons Increases intracellular
calcium
Production of reactive
nitrogen and oxygen
species
Hepatic encephalopathy
(Deleterious?)
[22] Liver Sinusoid Endothelial
cell
Phosphorylation of
endothelial-NO-synthase
NO synthesis and release in
liver
Increased hepatic blood
ﬂow
[23,24] Biliary epithelium CFTR activation HCO3− secretion in biliary
tree
Protection against ﬁbrosing
cholangiopathies
[19,20,59,77,81] Enteric nervous system – Intestinal secretion and
intestinal motility
Exacerbation of irritable
bowel syndrome
[39,51,33] Gut dendritic cells – Intestinal permeability and
immune response
Improvement of
inﬂammatory bowel
diseases
[35,45] Gallbladder smooth muscle K ATP channels Gallbladder ﬁlling Gallstone formation
[73] Pancreatic acinar cells Intra acinar cell calcium
transients
Activation of digestive
zymogens in acini
Aggravation of acute
pancreatitis
[56,91] Gastric carcinoma cells EGFR Activation of mitogen
protein kinases
Upper GI tract
carcinogenesis?
[90] Oesophagal
adenocarcinoma cells
NADPH oxydase NOX5-S
expression
Reactive oxygen species
production
[55,57] Liver carcinoma cells Decrease STAT 3
phosphorylation
Reduces tumorigenesis and
cell growth
Protection against
hepatocellular carcinoma
T4: thyroxine; T3: tri-iodothyronine; GLP-1: glucagon like peptide 1; IL: interleukin; TNF-: tumour necrosis factor alpha; NO: nitric oxide; CFTR: cystic ﬁbrosis trans-
m sium 
d
a
O
c
f
c
o
w
a
t
t
w
c
o
c
a
d
c
a
m
a
b
9
a
a
m
N
I
e
uembrane conductance regulator; K ATP: adenosine triphosphate sensitive potas
inucleotide phosphate.
 new pharmacodynamic approach to treat atherosclerosis [65,66].
f potential signiﬁcance, in a recent clinical pilot prospective
linical study one of the authors of this review (H.D) observed dif-
erences in the bile acid proﬁles in sera of patients with or without
oronary atheroma; speciﬁcally, a decreased plasma concentration
f lithocholic acid, known to be the most potent activator of TGR5,
as found. Lithocholic acid was the only predictor of coronary
theroma independently of patient gender [67]. It is possible that
he decreased lithocholic acid concentration in serum may  reduce
he TGR5 anti-inﬂammatory signalling on macrophages, thereby
eakening a natural brake against plaque formation. This new
oncept warrants further investigations to determine the validity
f this clinical observation and whether the lithocholic acid con-
entration in sera can be used as a predictive marker indicating
theroma status or susceptibility in patients with cardiovascular
isorders.
Overlapping metabolic and hepatic disorders, such as in nonal-
oholic fatty liver disease, are also potential targets of future TGR5
gonists: histopathological analysis of the liver in the obese db/db
ice model of obesity, diabetes, and dyslipidemia, shows that the
dministration of a dual FXR and TGR5 agonist (INT 767) decreases
oth steatosis and inﬂammation [68].
.2. Hepatic and pancreatic disorders
Haemodynamic and vascular hepatic disorders result from
lterations of sinusoidal vessels, examples being peliosis hep-
tis [69] or focal nodular hyperplasia [70]. Such pathologies
ay involve TGR5, which is known to induce the synthesis of
O, an effective vasodilator, in liver sinusoidal endothelial cells.
n cirrhosis, the potential deleterious role of TGR5 in hepatic
ncephalopathy, a neuropsychological disorder caused by liver fail-
re, seems worth investigating. This is based on the evidence thatchannel; EGFR: epidermal growth factor receptor; NADPH: nicotinamide adenine
TGR5 activation by bile acids in cultured astrocytes and neurons has
been linked to an intracellular increase in Ca2+, and the generation
of reactive oxygen species [17]. These mediators may contribute
to the feed-forward loop of hepatic encephalopathy. Interestingly,
a marked downregulation of TGR5 mRNA expression has been
observed in human cerebral cortex from cirrhotic patients com-
pared to healthy subjects [17]. Ammonia, for long suspected to play
a major role in the pathogenesis of hepatic encephalopathy, directly
reduces TGR5 expression in cultured astrocytes, suggesting here a
downregulation of the receptor in response to chronic elevation of
the circulating ligands [17,71,72].
Other studies showed that genetic deletion of TGR5 protects
against gallstone formation in mice [10]. We  can speculate that
TGR5 may  play a role in gallbladder lithiasis and its consequences.
Indeed, TGR5 activation induced gallbladder ﬁlling [45] through
the inhibition of biliary smooth muscle cell activity or, possibly,
the stimulation of sphincter of Oddi contraction (or both) [35].
However, it is not known whether patients with gallbladder lithi-
asis have different TGR5 expression in the gallbladder. A recent
study suggests that TGR5 should have a protective role in human
hepatocellular carcinoma [57].
Acute pancreatitis may  also be linked to TGR5. In TGR5-
knockout mice, acute biliary pancreatitis is associated with lower
“hyperamylasemia, oedema, inﬂammation, and acinar cell injury”
[73]. Whether changes in TGR5 signalling inﬂuence the severity of
pancreatitis in clinical setting is worth exploring.
TGR5 is present in bile ducts, where its activation stimu-
lates local bicarbonate secretion [24]. However, attempts to ﬁnd
sequence variations in the TGR5 gene associated with primary
sclerosing cholangitis (PSC), have not been successful, despite the
initially promising results [2,15,74]. The genome-wide association
studies performed in patients with PSC, have revealed a statis-
tically signiﬁcant association between the TGR5 gene locus with
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SC and ulcerative colitis. A single-nucleotide polymorphism in
he noncoding region of exon 1 was statistically associated with
SC in different cohorts. Moreover, by sequencing the TGR5 gene
rom 267 patients with PSC, and by cloning epithelial cell lines
ith mutated TGR5 sequences in patients, Hov et al. identiﬁed ﬁve
utations able to reduce or abolish TGR5 function [15]. Therefore,
GR5 variants may  contribute to disease susceptibility and inﬂu-
nce disease course; however, their overall relevance for disease
athogenesis appears to be minor. Chronic cholestatic disorders
re also known to induce itching, which is highly distressing for
atients. Historically, the cause of such cholestatic pruritus has
een attributed to increased plasma and skin concentrations of
ile acids, although there is an imperfect correlation between the
egree of bile acid retention and the magnitude of itching. A few
ears ago, the lysophosphatic acid was proposed as the prurito-
en. A recent experimental study in mice may  open new venues
o elucidate the role of bile acids in cholestatic pruritus by show-
ng an implication of TGR5. Bile acids activate mouse dorsal root
anglia via TGR5-mediated activation of gastrin-releasing peptide
eurons that mediate pruritus. Interestingly, mice overexpressing
GR5 exhibit spontaneous pruritis, and TGR5-knockout mice itch
ess than WT mice after intradermal injections of TGR5 agonists.
his fascinating study suggests a new approach to the treatment of
his distressing problem [18].
.3. Inﬂammatory bowel diseases and Irritable bowel syndrome
PSC is strongly linked to inﬂammatory bowel disease (IBD),
ainly ulcerative colitis, affecting up to 80% of the patients with
holangiopathy [74,75]. The anti-inﬂammatory properties of TGR5
n immune cells suggest that TGR5 activation might be beneﬁcial in
nﬂammatory diseases. In addition, some genetic arguments exist
o involve TGR5 in IBD. The TGR5 gene locus is on chromosome
q35, close to a genetic variant (single-nucleotide polymorphism
s12612347) associated with both PSC and ulcerative colitis [15].
n a recent study, TGR5 has been found to be increased in an
xperimental model of colitis and in the colon of Crohn’s disease
atients [33]. Another work showed that in human lamina pro-
ria mononuclear cells isolated from Crohn’s disease patients, the
RNA expression of TGR5 was upregulated in patients with inﬂam-
ation compared to non-inﬂamed cases [76]. This was combined
ith an anti-inﬂammatory effect of secondary bile acids marked by
 decrease in TNF-alpha production of macrophages that should be
 compensatory mechanism to counterbalance the vicious circle of
nﬂammation in IBD.
The preferential localization of TGR5 on sensory and motor neu-
ons of the gut seem to indicate its potential involvement in gut
otor function and visceral sensitivity. Functional bowel disor-
ers, such as irritable bowel syndrome (IBS) [77], are characterized
y abnormal bowel movements [78] and visceral hypersensitivity
79,80] as the hallmark of the disease. TGR5-knockout mice have
 higher transit time and a lower defecation rate [59]. In humans,
amilleri et al. tested whether there was an association between
ingle nucleotide polymorphism in the TGR5 sequence and IBS
henotypes (predominantly characterized by diarrhoea and consti-
ation) in 414 patients. Their results indicate a potential association
etween TGR5 exon 1 polymorphisms and the overall transit time
n a subgroup of patients [81]. As previously noted, the TGR5-
nockout mouse exhibits microscopic changes in colonic epithelial
tructure and alteration of epithelial tight junctions, inducing an
bnormal increase in epithelial permeability, reported as a con-
ributing mechanism in the pathophysiology of both IBD [62] and
BS [82,83].
Of interest, the two most powerful natural agonists of TGR5
re lithocholic (3-monohydroxy) and deoxycholic acid (3,12-
ihydroxy) [9]. As noted before, in humans these bile acids Disease 46 (2014) 302–312 309
are formed by bacterial 7-dehydroxylation of the primary bile
acids, chenodeoxycholic acid (37-dihydroxy) and cholic acid
(3,712-trihydroxy). Ursodeoxycholic acid (3,7-dihydroxy)
is widely used in the treatment of primary biliary cirrhosis, and
in humans this bile acid can also be formed by bacterial epimeri-
zation of chenodeoxycholic acid [84]. Bacterial 7-dehydroxylation
is mediated by strictly anaerobic bacteria and occurs only in the
colon by a complex biochemical pathway involving a 4 6 – inter-
mediate. In humans, lithocholic acid and deoxycholic acid are the
dominant faecal bile acids and can, in principle, signal to TGR5 that,
if expressed, is localized on the apical membrane of colonic epithe-
lial cells. Lithocholic acid, however, has an extremely low aqueous
solubility at body temperature, and it seems unlikely that its con-
centration would be sufﬁciently high to activate TGR5 and cause
GLP-1 release. Moreover, patients who take ursodeoxycholic acid
for liver or biliary disease convert it entirely to lithocholic acid, and
an improvement in diabetic status has never been reported in these
patients.
A small fraction of lithocholic acid is absorbed from the colon
and passes to the liver where it is efﬁciently removed. Upon enter-
ing the hepatocyte, lithocholic acid is not only conjugated with
taurine or glycine, but is also sulphated, at least in humans. The
sulphated lithocholic acid conjugates are secreted into bile and are
not absorbed from the small intestine. The plasma concentration
of unsulphated (but amidated with taurine or glycine) lithocholic
acid is very low – probably less than 0.5 M – and more than 95% is
bound to albumin. Thus, it remains uncertain whether the very low
concentration of lithocholyl conjugates in plasma could activate
TGR5.
Deoxycholic acid is absorbed to a much greater extent – about
20–50% of that formed in the colon. Deoxycholic acid is efﬁciently
extracted by the liver, conjugated with taurine or glycine, and circu-
lates with the primary bile acids. Postprandial concentrations are in
the range of 1–3 M.  In cholestasis, the proportion of deoxycholic
acid in the circulating bile acids diminishes as cholestasis worsens.
In mouse, primary bile acids differ from man. There are only
two – the taurine-conjugated -muricholic acid (3,6,7-
trihydroxy-) and cholic acid. When the -muricholic acid
undergoes 7-dehydroxylation, murideoxycholic acid (3,6-
dihydroxy) is formed. Its EC50 for TGR5 activation is 4.9 M,  about
10 times higher than that of lithocholic acid and 4 times higher
than that of deoxycholic acid.
A recent study [61] from the laboratories of Auwerx and Schoon-
jans has presented convincing evidence that release of secondary
bile acids from bile acid sequestrants results in TGR5 activation
and GLP-1 release in mice, thus providing a mechanism for the
well-known antidiabetic effects of bile acid sequestrants.
It seems remarkable that the stimulus for activation of TGR5
should be a secondary bile acid. Yet, in most mammals there
is a symbiotic relationship between the whole organism and its
microbiome in the distal intestine, and one way for the micro-
biome to communicate to its host could be via secondary bile acids.
Such an evolutionary development means that there would be less
signalling during the ﬁrst year of life when the anaerobic ﬂora had
not developed, or in animals lacking an anaerobic cecum where
7-dehydroxylation occurs.
9.4. Gastrointestinal cancer
Because some, but not all, epidemiological studies have shown
an association between high levels of faecal bile acids and colon
cancer [85,86], bile acids have been long suspected to be involved
in colon carcinogenesis [87]. However, their role still remains con-
troversial based on in vitro dual effects of bile acids on apoptosis and
cell proliferation. Nonetheless, a recent study [88] shows that when
deoxycholic acid is fed at a level of 0.2% in the diet does induce colon
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ancer in mice. A possible mechanism is the suppression of miR-
99, which targets CAC1, a cell cycle-related protein, and thereby
cts as a tumour suppressor [89].
TGR5 has not been associated with colonic carcinogenesis,
hereas two in vitro studies have shown an implication of the
eceptor in gastric [48] and oesophageal carcinoma [90]. In humans,
astroduodenal reﬂux occurs as a complication of distal gastrec-
omy. The reﬂux of bile acids into the stomach and oesophagus
s reported to increase the risk of gastric or oesophageal cancer
90–92]. TGR5 is implicated in the activation of carcinogenic path-
ays in gastric carcinoma cell lines [56]. Moreover, TGR5 is able
o induce proliferation of human Barrett cell lines from Barrett’s
esophagus, an oesophageal metaplasic condition well-known for
ts risk of developing into oesophageal adenocarcinoma [56,90]. A
ecent clinical study analysing by Kaplan–Meier curves the sur-
ival of 171 patients with gastric adenocarcinoma showed that the
reater the TGR5 immunoreactivity found in gastric adenocarci-
oma specimens, the worse the patient survival [93].
A report from Chen et al. offers perspectives in human liver car-
inogenesis, where TGR5 should have a protective role in human
epatocellular carcinoma [58].
0. Conclusion
Since the original characterization of TGR5 in 2002, a grow-
ng number of studies have explored not only TGR5 expression
t both the gene and protein levels in various tissues but also the
esults of its activation on several intracellular signalling pathways.
ile acid conjugation with taurine renders bile acids’ membrane
mpermeable; however, the discovery of TGR5 function provides a
echanism by which conjugated bile acids can inﬂuence cellular
ctivity without entering the cell. Several TGR5 signalling pathways
ctivated by bile acids appear to be promising targets for the treat-
ent of gastrointestinal diseases. Decreased pruritus in cholestatic
iver disease, improvement of insulin resistance in type 2 diabetes,
rotection against obesity, and inhibition of atheroma develop-
ent are pointed out as potential therapeutic approaches based
n ligand–TGR5 interaction. Anti-inﬂammatory effects, especially
n TNF- secretion in monocytes could lead to the development of
ew molecules to curtail inﬂammatory diseases, such as rheuma-
oid arthritis and IBD. Clinical trials are needed to test whether the
ew semi-synthetic TGR5 agonists have clinical efﬁcacy in any or
ll of these conditions.
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